10 recruiting, 7 completed, 7 not yet recruiting, 6 unknown. 29 Phase 2, 6 Phase 3, 2 Phase 1, 2 Phase 4, 1 Not applicable.
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) Trilaciclib, Eribulin - Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-11-04 | 2025-12-01 |
| Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer Trilaciclib, Saline (0.9% NaCl) - Limited Stage Small Cell Lung Cancer | Phase 3 | Recruiting | Pharmacosmos A/S | 120 | 2026-09-01 | 2026-10-02 |
| A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs Trilaciclib and Topoisomerase I inhibitor type ADC drugs - Tumor Patients | Not applicable | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2026-07-01 | 2026-07-30 |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| Trilaciclib Combined With Immunochemotherapy for R/M HNSCC Trilaciclib - Head & Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 32 | 2026-06-01 | 2026-07-01 |
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib, Tislelizumab, Cisplatin, Gemcitabine - Bladder Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 210 | 2025-10-01 | 2025-02-21 |
| Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC Trilaciclib + Cisplatin - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Hunan Cancer Hospital | 30 | 2024-12-30 | 2024-12-31 |
| Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trilaciclib - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | Shandong Cancer Hospital and Institute | 30 | 2024-12-15 | 2024-12-03 |
| Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma Trilaciclib, Pirarubicin, Lobaplatin - Osteosarcoma | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-11-13 | 2024-12-03 |
| A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib Chemotherapy, Trilaciclib Injection [Cosela] - Ewing Sarcoma, Myelosuppression | Phase 2 | Recruiting | Fudan University | 22 | 2024-10-31 | 2024-11-21 |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib - Lung Cancer, Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 52 | 2024-10-13 | 2024-11-21 |
| Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer Trilaciclib Injection [Cosela], Placebo - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2024-07-09 | 2024-08-26 |
| Trilaciclib Prevents Myelosuppression With Chemoradiotherapy Trilaciclib - Myelosuppression | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-06-26 | 2024-09-24 |
| the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Trilaciclib - Non-small Cell Lung Cancer | Phase 2 | Enrolling by invitation | Henan Cancer Hospital | 41 | 2024-04-02 | 2026-01-28 |
| Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma Trilaciclib Injection [Cosela] - ESCC | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2024-04-02 | 2024-11-21 | |
| Myeloprotection With Trilaciclib in Pan-cancer Population Trilaciclib Injection, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 132 | 2024-03-01 | 2024-03-07 |
| Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma Trilaciclib - Osteosarcoma | Phase 2 | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 20 | 2024-02-01 | 2024-01-22 |
| Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer Trilaciclib, Pembrolizumab, Gemcitabine - Metastatic Triple-Negative Breast Cancer | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 36 | 2024-01-10 | 2026-08-20 |
| Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Trilaciclib, Placebo, Topotecan - Extensive-stage Small-cell Lung Cancer | Phase 4 | Active not recruiting | Pharmacosmos A/S | 302 | 2023-10-13 | 2026-10-05 |
Showing 20 of 40. Sign in to see all of them.
Small Cell Lung Carcinoma (10) · Breast Neoplasms (8) · Triple Negative Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Lung Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Osteosarcoma (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemangiosarcoma (1)
G1 Therapeutics, Inc. (11) · Jiangsu Simcere Pharmaceutical Co., Ltd. (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Pharmacosmos A/S (2) · Sun Yat-sen University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Henan Cancer Hospital (1) · Hunan Cancer Hospital (1) · Peking University People's Hospital (1) · QIAO LI (1) · QuantumLeap Healthcare Collaborative (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Chest Hospital (1)
China (22) · United States (14) · Spain (6) · France (4) · Bulgaria (3) · Georgia (3) · Hungary (3) · Poland (3) · Ukraine (3) · Belgium (2) · Croatia (2) · Moldova (2) · North Macedonia (2) · Serbia (2) · Slovakia (2)
Antoinette Tan, MD (1) · Jared Weiss, MD (1) · Laura Esserman, MD, MBA (1) · Lei Deng, PhD (1) · Qiang Liu, Doc (1) · Qiao Li (1) · Shusen Wang, MD (1) · Tianxin Lin, Ph.D (1) · Xiao L Ge, PHD (1) · Xiaolin Ge, PHD (1) · Ying Cheng, Doctor (1)
PMID 34405547, PMID 34408488, PMID 33595690, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 31504118, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33004541, PMID 33123968, PMID 34529000, PMID 34741021, PMID 34777341, PMID 34873975, PMID 35623341, PMID 35842567, PMID 35993306, PMID 36069821, PMID 36135712, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39113428, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39579142, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41810725, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946
2016 (3), 2017 (1)